Thomas S.
- Country
- Austria
- Department
- Clinical Division of Endocrinology & Metabolism
Research Overview
- Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
- Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study
- Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Trial
Data & Insights
Has run more than one trial at 662 of 1424 partner sites.
Specializations
Renal Medicine
The investigator specializes in treating complex chronic kidney disease conditions, with particular focus on patients requiring hemodialysis and those with high proteinuria. Their research encompasses innovative therapeutic approaches for end-stage kidney disease (ESKD).
- Dialysis Management
- Proteinuria Treatment
- ESKD Complications
Metabolic Disorders
Their expertise extends to managing complex metabolic conditions, including type 2 diabetes and severe hypertriglyceridemia. The investigator focuses on novel therapeutic approaches for patients with concurrent obesity and metabolic disorders.
- Diabetes Management
- Lipid Disorders
- Weight Management
Cardiovascular Medicine
The investigator has significant experience in treating atherosclerotic cardiovascular disease, particularly in patients with renal complications. Their work includes evaluation of cardiovascular outcomes in patients with left ventricular hypertrophy.
- Cardiovascular Risk Management
- Atherosclerosis Treatment
- Cardiac Complications in Kidney Disease
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.